title: Juvenile myasthenia gravis with prepubertal onset.
abstract: Juvenile myasthenia gravis (JMG) with prepubertal onset is an uncommon disease. We studied 19 patients with age at onset ranging from 1.5 to 9.2 years and compared their clinical characteristics and response to therapy with 114 cases with MG onset after the prepubertal age, up to 20 years. Neither sex prevalence nor autoimmune diseases other than MG were found in younger patients. Although ocular myasthenia was more frequent than in later-onset JMG, children with generalized symptoms were often severely affected and respiratory involvement was present in 8/19 patients. Anti-acetylcholine receptor antibodies were detected at a lower rate and, in contrast with results in older patients, seronegativity was more frequent among children with generalized disease. Three out of six patients with onset before the age of five showed spontaneous remission. Nine prepubertal patients underwent thymectomy and, as most of them also received immunosuppressive therapy, the influence of surgery on disease outcome remains unclear; in no case was thymoma found. This is in contrast to the good results after thymectomy and the presence of thymoma in the later-onset group. Eleven patients in the prepubertal series were treated with immunosuppressive therapy. At the end of follow-up, most patients were in good condition. The frequency of immunosuppressive therapy and the rate of good therapeutic results did not differ from those observed in older patients.
authors: Institute of Neurology, Catholic University, Rome, Italy. a.evoli@vsb.it
authors: A
authors: A
authors: Evoli
authors: A P
authors: AP
authors: Batocchi
authors: E
authors: E
authors: Bartoccioni
authors: M M
authors: MM
authors: Lino
authors: C
authors: C
authors: Minisci
authors: P
authors: P
authors: Tonali
mesh_terms: D000293:Adolescent; D017668:Age of Onset; D001323:Autoantibodies / Q000097:blood; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D004358:Drug Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D008297:Male; D009157:Myasthenia Gravis / Q000097:blood / Q000453:epidemiology* / Q000628:therapy*; D011627:Puberty; D011950:Receptors, Cholinergic / Q000276:immunology; D012074:Remission Induction; D013934:Thymectomy; D016896:Treatment Outcome
chemical_list: D001323:Autoantibodies; D011950:Receptors, Cholinergic